Boston, MA Clinical Trials Report — April 2026

For individuals in Boston, MA, considering participation in clinical research, April 2026 presents a critical window for joining studies before enrollment concludes. Across the city, 231 clinical trials are scheduled to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 50 of these rapidly closing studies are still actively seeking participants without specific health conditions. Those interested in contributing to medical advancements should explore these options promptly.

Upcoming Deadlines for Research Participation

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on neurological conditions, various cancers, and cardiovascular health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder (5 trials)
• Prostate cancer (4 trials)
• Stroke (4 trials)
• Sleep (3 trials)
• Leukemia (3 trials)
• Ovarian cancer (3 trials)
• Depression (3 trials)
• Amyotrophic lateral sclerosis (3 trials)
• Adenoid cystic carcinoma (3 trials)
• Coronary artery disease (3 trials)

This month, Boston saw the opening of 29 new clinical trials, a decrease from the 34 trials that launched in March 2026. Despite this slight dip in new openings, the city continues to be a vibrant hub for medical research, with a total of 2,642 clinical trials currently recruiting across 640 research facilities.

Spotlight on New Research Opportunities

April brings several notable new trials to Boston, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Dana-Farber Cancer Institute is sponsoring NCT07513324, "Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)." This Phase 2 study, aiming for 116 participants, assesses risk for HPV-driven oropharyngeal cancers using blood tests and clinical features to determine appropriate treatment.
• Massachusetts General Hospital is leading NCT07527117, "Role of n On-contrast Chest CT (NCCT) Based CT V: Q in Patients With Acute Pulmonary Embolism (aPE)." This study, aiming for 750 participants, investigates if a CT scan without contrast dye can help detect pulmonary emboli.
• Carelon Research is sponsoring NCT07525843, "A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study." This trial, designed for 390 participants, explores if an online well-being program can help teens with congenital heart disease improve stress management.
• Tufts Medical Center is initiating NCT07519876, "Pulmonary Embolism and Right-to-Left Shunts." This study aims to understand the connection between patent foramen ovale (PFO) and pulmonary emboli in 256 participants.
• An observational study, NCT07518134, "A Study of Uveitis in Children <18 Years of Age," sponsored by Jaeb Center for Health Research, will collect data on clinical features and treatments in 300 children with uveitis.

New trials this month are exploring a range of conditions, including acute lymphoblastic leukemia, lymphomas, acute myeloid leukemia, advanced urothelial cancer, alopecia areata, asthma, and amyloidogenic transthyretin (ATTR) amyloidosis. Drug trials account for the majority of new studies, with 11 new drug trials, followed by 7 behavioral trials and 4 other types of studies.

For individuals without a specific medical condition, there are significant opportunities to contribute. 3 of the new trials launched this month are actively seeking healthy volunteers. Across Boston, a total of 318 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Boston's Leading Research Institutions

Boston is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Massachusetts General Hospital (609 trials)
• Dana-Farber Cancer Institute (558 trials)
• Brigham and Women's Hospital (327 trials)
• Beth Israel Deaconess Medical Center (266 trials)
• Boston Children's Hospital (224 trials)
• Tufts Medical Center (113 trials)
• Boston Medical Center (98 trials)
• Research Site (62 trials)
• Massachusetts General Hospital Cancer Center (61 trials)
• Boston University (24 trials)

These institutions offer a broad spectrum of research, from oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center, to diverse medical fields at Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, and Boston Children's Hospital.

Broadening Your Search: Nearby Options in Massachusetts

While Boston offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Massachusetts. Cities with active trials include Worcester (4 trials), Malden (2 trials), Charlestown (1 trial), Framingham (1 trial), Bedford (1 trial), Quincy (1 trial), Rockland (1 trial), and Waltham (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 29 new trials launched this month, 18 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 10 new trials include children, 3 are female-only, and 1 is male-only. Academic institutions continue to play a vital role in Boston's research ecosystem, with Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, and Boston Children's Hospital sponsoring the majority of new trials. Industry sponsors like Eli Lilly and Company and Incyte Corporation are also driving significant research efforts.

As we move further into spring, Boston's robust research community will continue to drive medical innovation, with ongoing enrollment in these significant Phase 2 and 3 trials and the exploration of new therapeutic strategies across a wide range of health conditions.